EventsThe 4th International Electronic Conference on Cancers
Published
This submission belongs to the session Session G. Cancer Therapy of the event The 4th International Electronic Conference on Cancers
Published date
27 Mar, 2024
Academic Editor
author-avatarUlrich Pfeffer
Citation
Yoshiki Fujikawa, Shinji Kawabata, Kohei Tsujino, Hideki Kashiwagi, Yusuke Fukuo, Ryo Hiramatsu, Toshihiro Takami, Masahiko Wanibuchi, Takushi Takata, Hiroki Tanaka, Minoru Suzuki, Naonori Hu, Shin-Ichi Miyatake, Ryo Kayama, Exploring BNCT as a Novel Approach for Metastatic Spinal Tumor Management, in Proceedings of The 4th International Electronic Conference on Cancers, 6 March–8 March 2024, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Exploring BNCT as a Novel Approach for Metastatic Spinal Tumor Management

image
Ryo Kayama 1
Yusuke Fukuo 1
Takushi Takata 2
Hiroki Tanaka 2
Masahiko Wanibuchi 1
1. Osaka medical and pharmaceutical university, Japan
2. Institute for Integrated Radiation and Nuclear Science, Kyoto University, Japan
3. Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Japan
Abstract

[Background] Boron neutron capture therapy (BNCT) is a particle beam therapy that enables the precise targeting of tumors at the cellular level. Building on the success observed in nuclear reactors, BNCT exhibits potential as a therapeutic approach for managing invasive brain tumors, including malignant gliomas and high-grade meningiomas. Metastatic spinal tumors have been treated by surgical removal, radiation therapy, and a variety of other multidisciplinary therapies. However, none of them has been successful in overcoming this metastatic disease. This study aimed to assess the efficacy of BNCT in treating metastatic spinal tumor using a mouse model.

[Methods] In vitro experiment: neutron irradiation was applied to A549 human lung carcinoma cells with (BNCT group) or without p-boronophenylalanine (BPA) 10 µg Boron/ml for 24 h exposure before irradiation (hot control group) for 0 to 30 min. The cell killing effect was assessed by a colony forming assay. In vivo experiment: an A549 subcutaneous tumor was removed and implanted into the lumbar lamina, where it was partially resected. A few weeks later, metastatic spinal tumor models were successfully established. For the biodistribution of boron, after 2.5, 6, or 24 h of intravenous BPA administration (250mg/ mouse body weight), the metastatic spinal tumor models were sacrificed and the boron concentration of the tumor and each organ measured using Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES).

[Results] In vitro neutron experiment: the BNCT group showed a greater cell killing effect than the hot control group. The highest boron accumulation in the tumor was observed at 2.5 h after BPA administration (8.6 µg B/g), and the tumor to normal spinal cord ratio (T/N) was 2.7 and the tumor to blood ratio (T/Bl) was 2.8.

[Conclusions] The findings may indicate that BNCT represents an effective approach in the management of metastatic spinal tumor. We will perform an in vivo neutron irradiation experiment on this model to evaluate the effects of BNCT on survival and neurological function.

Keywords
BNCT
metastatic spinal tumor
radiation therapy
Oral Presentation
Hippocampus-sparing volume-modulated arc therapy (HS VMAT) for patients with World Health Organization grade II gliomas: a feasibility study
Exposure to mycovirus-containing Aspergillus flavus alters transcription factors in normal and leukemia cell lines